march 27, 2016 august 2016 complimentary service of ... · its 2nd edition (2012), and wrote sme...

1

Audrey’s Life Science Meeting Picks for March 27, 2016 – August 2016

Complimentary Service of AudreysNetwork.com

March 27, 2016

*****************************************************************

Bio2Device Group, Tuesday Morning, March 29, 2016

Topic: “The Future of Medical Innovation: How Value Based Purchasing (VBP) and Bundled

Payments Will Transform the Industry”

Speaker: Ted Kucklick , President and CTO, Cannuflow Inc.

Date and Time: Tuesday, March 29, 2016, 8:30 am

Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA

There is no fee nor registration required for morning meetings.

Topic Description

The landscape for innovation in medical devices has changed radically in just the last 5

years. Changes in the global macroeconomic environment, regulation, industry consolidation

and new categories of medical device buyers with different needs driven by value

purchasing mandates have shifted the landscape, and will continue to do so. In this talk

learn about these new challenges and opportunities and how to meet them and potentially

benefit from them.

Speaker Bio

Ted Kucklick is founder and CEO of Cannuflow, Inc., a company dedicated to innovative

technologies for arthroscopic surgery. He has worked in R&D of innovative medical devices

for numerous companies including RITA Medical (RITA) acquired by ANGO, AfX, (acquired

by Guidant) Somnus (SOMN) acquired by Smith and Nephew, Sleep Solutions (now

Novasom) and Starion Instruments (acquired by Pentax). Ted has a degree in product

design, and a certificate from the UC Berkeley Haas School of Business Bio-Entrepreneur

program. He is a member of the IEEE/EMBS and AMI (medical illustration) societies and an

inventor on over 100 issued patents. Ted wrote The Medical Device R&D Handbook, now in

its 2nd edition (2012), and wrote SME video production, Medical Applications of Rapid

Prototyping, and is a regular contributor to BoneZone and Medical Design Design magazine,

has been published in The Journal of Biomedical Ethics (Begel House) and is a frequently

invited speaker on the subject of medical device innovation. Ted is also a member of

Keiretsu Forum and Life Science Angels.

*****************************************************************

JLABS, Tuesday Afternoon, March 29, 2016

Topic: “Choose Your Exit: How to Benefit from IPO Preparation”

Speakers:

Matthew Hudes | US Managing Principal, Biotechnology, Deloitte Consulting LLP,

Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP

Date and Time: Tuesday, March 29, 2016

Agenda:

12:00 PM | Registration Opens, Lunch and Networking

12:40 PM | Life sciences company - life events

1:10 PM | Financing strategies

1:30 PM | Exit strategy: M&A vs. IPO

1:50 PM | IPO requirements - Job Act

2

2:20 PM | Coffee Break

2:30 PM | Ready for IPO?

3:00 PM | Going through the IPO process

3:30 PM | Company post IPO

3:50 PM | Next events: IPO readiness bootcamp; Lessons learned

4:00 PM | Program Close

Location: JLABS, 329 Oyster Point Blvd - 3rd Floor, San Francisco, CA

Fees:

$30 | General Public

$45 | Onsite

Details and registration at http://www.eventbrite.com/e/choose-your-exit-how-to-

benefit-from-ipo-preparation-tickets-20106147027?aff=weekly

Topic Description

The business development professional's purpose is to optimize optionality and long

term value at each stage of a company's life. As a company grows and gains traction,

it's easy to get enticed and overwhelmed by the numerous opportunities that arise.

How do you determine the direction that will add the most value to your company?

How do you avoid the constant pursuit of "shiny objects?" How do you know when it's

the right time for a strategic partnership?

At this event, you will learn how to prepare your company for IPO as well as the key

differences between M&A and IPO exits. Key focus areas include:

• What are the key decisions you need to make and when do you need to make

them?

• When is the right time to develop your exit strategy?

• Key considerations and differences between M&A and IPO exits

• Job Act requirements

• SEC requirements for IPO and post IPO

• Key stakeholders to manage through the IPO process

• Company’s internal processes pre- and post-IPO

Deloitte will share their experiences working with startup life sciences companies

through the IPO process and beyond. The skills learned during this program are

valuable to all young companies whether or not they eventually go through an IPO.

This "How to... Workshop" is geared towards life sciences startups.

As with all of our events, the "How to... Workshop" is interactive and informal so

bring your questions with you!

Speakers' Bios

Matthew is the BioPharma segment leader for Deloitte’s Life Sciences practice sector.

He speaks frequently about such topics as fostering innovation, personalized

medicine, the use of technology for innovating clinical research, finance

transformation, manufacturing and quality, regulatory compliance, and supply chain.

Matthew is the executive sponsor of Deloitte’s unique innovation collaboration with

the University of California, and is the Lead Client Service Principal for the California

Institute for Quantitative Biosciences (QB3). He is a member of the Board of

Directors of BIOCOM and of the Bay Area BioEconomy Initiative, and a faculty

member and executive sponsor of the UC Berkeley BioExec Institute.

Angela has 20 years of experience serving both public and private companies with a

focus on the life sciences industry. She works with companies in all stages of growth,

from start-ups to SEC registrants. Her technical background includes complex

3

accounting issues such as revenue recognition, equity, derivatives, stock-based

compensation, and acquisitions. Angela has been involved in financing and M&A

transactions, including initial public offerings, offerings in leveraged buyouts, and

several secondary shares offerings. She has extensive international experience and is

a certified public accountant in the United States and the United Kingdom. Angela

also served as a CFO before returning to public accounting in 2003.

********************************************************************

7th Annual Bay Area Biomedical Device Conference, Wednesday , March 30, 2016

Date and Time: Wednesday, March 30, 2016, 8:30 am

Location: Student Union Ballroom at San Jose State University.

Registration information at www.biomedconference.org.

Conference Information

The 7th Annual Bay Area Biomedical Device Conference, hosted by the Biomedical

Engineering Society at San Jose State University (SJSU), will be held on Wednesday March

30th, 2016 in the Student Union Ballroom on campus. This year's conference theme is

Medical Innovations in Silicon Valley.

Our morning Plenary Speakers are Richard Roth, who is the Chief Strategic Innovation

Officer at Dignity Health, and Dr. Hanmin Lee, who is the Surgeon-in-Chief at the UCSF

Benioff Childern's Hospital. There will be special sessions focusing on the Unmet Medical

Device Needs in Developing Countries, Human Factors Requirements for Medical Device

Design, Nanoscale Applications in Medicine, and Web-Connected Medical Devices, with

presentations from industry professionals and researchers in the forefront of their fields.

The afternoon plenary sessions will feature two panels: an Industry Panel on How to Build a

Medical Device Company from Scratch, and a CEO Panel that will focus on the Exit

Strategies for Medical Device Companies. Students from universities will be presenting their

research posters throughout the day. A Wine and Cheese Networking Reception is planned

for 5:15 to 7:00 p.m.

Further information about the conference, including registration information, can be found

at the conference website www.biomedconference.org.

Early registration for the conference ends Thursday, March 17th, 2016. Please register as

early as possible to take advantage of the reduced registration rate and to enable us to

make adequate preparations for hosting you.

If you have any questions or if your company is interested in being a sponsor, please email

us at [email protected].

We appreciate you forwarding this email and the attachment to any of your colleagues and

friends who may be interested in this conference or can benefit from it.

Guna Selvaduray, Ph.D.

Interim Chair, BCME Department

Director, Biomedical Engineering Program

Professor, Materials Engineering

College of Engineering

San Jose State University

San Jose, CA 95192-0082

Phone: (408) 924-3874

http://bcme.sjsu.edu/profile/guna-selvaduray

****************************************************************

ACRP Virtual Career Fair, Thursday Afternoon, March 31, 2016

http://www.biomedconference.org/

http://www.biomedconference.org/

mailto:[email protected]

http://bcme.sjsu.edu/profile/guna-selvaduray

4

Event: “Where Clinical Research Talent Meets Opportunity”

Date and Time: Thursday, March 31, 2016, noon til 4:00 pm Eastern Daylight Time

Register at

https://app.brazenconnect.com/events/ACRP033116#!eventLanding;eventCode=ACRP0331

16

This Online Career Fair will connect you directly with employers with open career

opportunities from the comfort of your home, office, smartphone or tablet.

As an attendee, you have the ability to explore employer information and opportunities.

Choose which employers you want to interact with and then engage in one-on-one text-

based conversations directly with a recruiter at those organizations. You can share your

background, experience, resume and ask questions. Maximize your time in the event by

getting in line to chat with representatives from more than one company at a time.

This Online Career Fair connects you in real time with employers seeking to recruit top

talent.

Who should attend:

Professionals seeking new career opportunities or exploring career options

Professionals who are ready to begin their careers

Professionals seeking to learn more about the various nationwide opportunities

Get a Reminder

Register Now

REGISTER

OR

REGISTER WITH LINKEDIN

Already registered? Login.

Are you an employer?

HOW THIS ONLINE EVENT WORKS

1

Register

Create your account and fill out the event registration form

2

Explore

Login anytime before the event to learn more about participating employers

3

Attend

On the event date and time, login and join the live session from anywhere

4

Connect

During the live event, you'll be matched in one-on-one timed chats with participating

employers

EDT)

********************************************************************

South Bay HBA, Saturday, April 2, 2016

Location: Shoreline Lake American Bistro - 3160 N Shoreline Blvd., Mountain View, CA

To RSVP or for more information, please contact Meggin Taylor or Mary Dosunmu

*************************************************************

Bio2Device Group, Tuesday Morning, April 5, 2016

Topic: “Microvolution’s Technology Empowers Scientists to Accelerate Medical Research with

Greater Accuracy”

Speakers: Cassandra Boyer and Marc Bruce, CEO & Co-Founder and CTO & Co-Founder,

Microvolution



5

Date and Time: Tuesday, April 5, 2016 - 8:30am

Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale

No registration or fees for morning meetings

Topic Description

Medical research discovery often lacks accuracy. It is also a very slow process. Currently,

scientists can wait days to get their microscopy images deconvolved (focused) via CPU-

based software; hence, productivity is lost, plus, failure rates are high because scientists

cannot make adjustments to their experiments in real-time. Advancements in software and

technology are poised to change that. Microvolution's real-time GPU accelerated

deconvolution software has the unique ability to offer accurately focused images from

fluorescence microscopes in seconds. What used to take one week to complete with a failed

outcome, can now be completed in one hour, with success.

Invented by Microvolution’s CTO while studying immunology at Stanford, this new

technology accelerates medical research up to 200 times faster and enables scientists to

make adjustments to their experiments in real-time. Data sets improve because more

images can be captured in less time. Additionally, the unique algorithms incorporated into

Microvolution’s software deliver enhanced accuracy for medical discovery. Microvolution

empowers scientists to accelerate their discovery with greater accuracy and can help them

decrease costs as they produce successful results.

Speaker Bios

Cassandra Boyer, MT (ASCP), CEO & Co-Founder drives the commercialization efforts and

operations at Microvolution. She’s also an Advisor for Stanford’s Medical School’s think-tank

called SPARK. At Microvolution, Cassandra implements lessons learned from having over 25-

years of success as a proven top-tier commercial leader at GE Healthcare and Beckman

Coulter in both the life sciences and clinical markets. She is also a board certified Medical

Technologist by the American Society of Clinical Pathology with experience in clinical

hematology.

Marc Bruce, PhD, CTO & Co-Founder invented Microvolution’s technology as a PhD student

at Stanford University while studying immunology. During his studies, Marc gained a unique

insight into bridging advanced wet lab techniques with computation and invented the

software technology to solve challenges in analyzing microscopy problems in immunology

and cell biology research. Marc published: Bruce MA, Butte MJ, Real-time GPU-based 3D

Deconvolution, Optics Express, 2013; 21(4): 4766. After finishing his PhD in September

2014, Marc developed this software into a viable commercial product via his extensive

experience in software development in C++, Java, CUDA, and other programming

languages.

****************************************************************

Medtech Frontiers, Thursday Evening, April 7, 2016

Topic: “Exorcising the Silicon Tunnel Vision”

Speaker: Oshiorenoya Agabi, Founder & CEO, Koniku Inc.

Date and Time: Thursday, April 7, 2016, 6-9 pm, talk starts at 6:45 pm

Location: Triple Ring Technologies: 39655 Eureka Dr., Newark, CA

The seminar is free, but registration is required for planning purposes. There may be a

small number of walk-in spots available.

Topic Description

It's evident that we have reached the limit of silicon technology. Over the last 5 years,

processor performance and transistor counts have largely stalled while costs are shooting

6

up! So, what are the alternatives? We have neuromorphic chips, quantum computers, 3D

transistors with "fins", and graphene-based processors on the table. However, a key

ingredient for the success of silicon is scale. How do each of these systems scale? How do

we characterize the power performance curves in each of these devices? Interestingly, these

devices are based on similar technologies -- silicon, or a variation thereof. As such, it's

prudent to investigate alternative technologies -- especially systems based on soft matter

that is biology. Biology is indeed the most advanced technology on the planet.

We have also observed that massive shifts in communication and computation have

occurred with a change in substrate. Koniku believes that applying neurons as a material

just like silicon will usher in the next change, and help us meet the impending

computational and communication challenges.

This talk will expound upon Koniku's progress in building a processor using real biological

neurons, and the company's immediate (3-5 years) and long term goals to increase the

neuron density on our chips. Lastly, there will be a discussion about the types of

applications, which may be possible with such devices.

Speaker Bio

Oshiorenoya Agabi (Founder & CEO, Koniku Inc.), has over 10+ years of experience in

neuroelectronic interfacing within both industry and academia. As a strategic program lead

at a robotics startup in Switzerland (Neuronics AG, acquired in 2008), Osh implemented

learning algorithms for pick-and-place robots which work alongside factory workers. The

team achieved significant success in developing robots that did not learn object

categorization autonomously.

Osh also led a cross disciplinary industry team to develop an in vitro reflex arc for modeling

implantable neural chips. These chips were to interface with the peripheral nervous system.

The project was completed with a successful design of an implantable chip lasting 30-40

years. While leading work in the applications of liquid state machines to biological neurons

on chip, this was completed for the first time in 2004 at the ETH Zurich (Eidgenössische

Technische Hochschule). Here, he developed applied criteria for computability of biological

neurons in vitro.

As a visiting scholar and PhD candidate at the Imperial College in London, Osh built 2

photon microscopes for studying synaptic transmission in the mouse. He also worked on

developing super resolved automated systems for stimulating optogenetic neurons with

addressable light systems. The intent was to understand the mapping of visual signals with

thalamocortical slices in vitro -- that is, "the various stages of visual information processing

in the brain."

MedTech Frontiers is a continuing series of free events for medical device and life science

investors, entrepreneurs, clinicians, and technologists. We have hosted over 60 of these

talks to foster innovation, community, and learn about emerging technologies beyond our

labs. Please join us for evenings of food, conversation, and presentations by Silicon Valley

luminaries held on the first Thursday of each month. Events are free, but registration is

requested for planning purposes. A limited number of on-site registrations are

available. All events start at 6pm and are held at Triple Ring Technologies, 39655 Eureka

Dr., Newark, CA 94560. Should you have questions or comments, feel free to email us at

[email protected].

*********************************************************************

7

BioX Program Stanford, Thursday Mid Day, April 7, 2016

Topic: “Optical Control and Interrogation of Protein Activity Using Engineered

Photoreceptors”

Speaker: Speaker: Bianxiao Cui, Department of Chemistry

Thursday, April 7, 2016, 12:00 pm

Location:

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360

SMALL LUNCH SERVED AT 12:00 pm LECTURES BEGIN AT12:15 pm


*************************************************************

JLABS, Thursday, April 7, 2016

Event: “Meet with…Sanderling Ventures”

Sanderling Representative: Timothy MillsTimothy Mills | Managing Director,

Sanderling Ventures

Date and Time: Thursday, April 7, 2016

Agenda:

10:30am | Registration Opens and Networking

11:00am | Presentation and Q&A

11:45am | Networking Lunch

1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be

approved. The application period ends on March 9th, 2016.

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor,

South San Francisco, California

Fees:

Presentation & Lunch


$35 | General Public Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of

one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch

will remain open until April 6th, 2016 (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-

one application period ends on March 9th, 2016. Your application will be reviewed

and you will be notified of acceptance by March 24th, 2016. Acceptance of a one-on-

one meeting is not guaranteed as all applications must be approved.

Register at http://www.eventbrite.com/e/meet-with-sanderling-ventures-tickets-

19488598924?aff=weekly

Topic Description

Sanderling is investing in today's seeds for tomorrow's harvest; is your technology

the next bumper crop?

Since 1979, Sanderling has been dedicated to building new biomedical companies,

utilizing a unique approach of specialized investment focus, active managing and long

term commitment. Sanderling has supported over 90 biomedical companies from very

early stage start-ups, through commercial development.

8

Investments are made at all stages with a focus on ground breaking early stage

technologies that reduce costs in hospitals. Currently they are investing Sanderling

VII which closed in 2015. Investment areas include:

Vaccines

Drug delivery

Research tools

Platform technology

Medical devices

Diagnostics

Imaging agents/devices

Digital/eHealth

Sanderling Ventures Managing Director Timothy Mills will be in attendance to give an

overview presentation about the company's key areas of interest. Following the

presentation, don't miss this opportunity to introduce yourself to Timothy during the

networking lunch. And finally, for those companies who apply online and are

approved, one-on-one meetings with Sanderling will provide an intimate forum to

discuss your company.

Sanderling Ventures Representative Bio

Timothy Mills has over twenty-five years of experience in biomedical research,

corporate management and venture capital investing. Dr. Mills joined Sanderling as

an Operating Partner in July 1998, was promoted to Managing Director in 2000 and

currently serves as the Chairman of the Investment Committee. At Sanderling, Dr.

Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and

i-Health. His active roles within Sanderling's portfolio companies include Chairman,

CEO, Director, and management team member. Portfolio companies previously

served include Stereotaxis (NASDAQ: STXS), Stentor, acquired by Royal Philips

Electronics (NYSE: PHG, AEX: PHI), CardioNet (NASDAQ: BEAT), Taligen

Therapeutics, acquired by Alexion Pharmaceuticals (NASDAQ: ALXN), Neomend,

acquired by C.R. Bard (NYSE: BCR), Sotera Wireless and InfraReDx (acquired by

Nipro Corporation). Currently, his roles also include Chairman of Torax Medical,

Pulsar Vascular and AdMIRx. Prior to joining Sanderling, Dr. Mills served as the

Corporate Vice President of New Business Development and Chief Scientific Officer of

Target Therapeutics, a medical device company that was acquired by Boston

Scientific (NYSE: BSX) in 1997 for $1.3 billion. From July 1994 to July 1997, he was

a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore &

Associates. Before joining Target in 1994, Dr. Mills served as Director of Business

Development and Advanced Research & Development in the Interventional Cardiology

Division of Baxter Healthcare, now Edwards Life Science (NYSE: EW). Dr. Mills'

previous academic appointments included Director of the Artificial Heart Program at

the University of California, Irvine Medical Center and faculty member at the

University of California, San Francisco Radiology Department. Dr. Mills received his

Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco

School of Medicine. He also received a M.S. in Electrical Engineering & Computer

Science from the University of California, Berkeley, and a B.S. in Electrical

Engineering from the University of Colorado, Boulder. In addition, he is an advisory

board member of the University of Colorado Technology Transfer Office and a

program faculty member of the Stanford University Biodesign program.

******************************************************

PBSS, Friday, April 8, 2016

9

Seminar luncheon: “Drug Repurposing for Unmet Medical Needs “

Speakers: Kevin Grimes, MD, MBA (Stanford University)

Date and Time: Friday, April 08, 2016, 11:00-13:30

Location: SF Bay Area: Foster City Crowne Plaza

Major Sponsor: Vendor show vendors registered to date: (6)Agilent; Cardinal Health;

Corning Life Sciences; DyChrom; Shimadzu Scientific Instruments, Inc; Thermo Fisher

Scientific, SID

Registration: http://www.PBSS.org

Registration deadline:4/6/2016 (it will close sooner if the seating cap is reached)

About the Topic

Drug repurposing, the development an existing drug for a new clinical indication, can be a

faster, less risky, and more cost-effective path for bringing a new therapy to patients in

need. The repurposed drug may already be approved for its original clinical indication or it

may have stalled in clinical development for lack of efficacy, unacceptable side effects, or

commercial reasons. In either case, the repurposing candidate has typically been

extensively studied in humans and should have a known safety profile. Drug repurposing

candidates may be identified in multiple way, for example: i) validating that the drug’s

original target is important in your disease of interest; ii) demonstrating that the drug has

activity against your new target through conducting a high throughput screen; iii) in silico,

by matching opposite gene expression signatures between the disease of interest and

known drug profiles; iv) through astute clinical observation and exploitation of known or

unanticipated side effects. Some drug repositioning programs can be commercially

attractive if they have intellectual property claims that block competitors (e.g., new

formulation, dosing regimen, route of administration) or can take advantage of privileged

regulatory status, such as orphan disease designation. Drug repurposing can be particularly

attractive for academics and other not-for-profit drug developers who are committed to

finding cures for patients, but have limited financial resources. Over the past nine years, the

Stanford SPARK program has moved over thirty repurposed compounds into clinical study.

About the Speakers

Kevin Grimes, MD, MBA is the Co-director of the SPARK Program in Translational Research

and an Associate Professor in the Department of Chemical and Systems Biology at the

Stanford University School of Medicine. He received his MD from Brown University and

completed his residency in internal medicine at Stanford University. He became a Clinical

Assistant Professor of Medicine at Stanford, where his primary duties included the teaching

and practice of internal medicine. Grimes received a Hartford Foundation Fellowship to study

health economics at the Stanford Graduate School of Business and obtained an MBA. He

was subsequently selected as a White House Fellow and assigned to the Department of

Defense, where he served as Special Assistant to the Secretary. He spent fifteen years in

industry, working in the medical device, life science consulting, and biotechnology sectors

prior to returning to Stanford to co-direct SPARK. In addition to SPARK, Grimes teaches

graduate student courses on drug discovery and development and continues to teach and

practice internal medicine. He has received the David Rytand Award for Excellence in Clinical

Teaching and the Faculty Award for Excellence in Graduate Teaching.

SPARK’s two-fold mission is to advance promising research discoveries into the clinic as new

therapeutics and diagnostics, and to educate faculty, post-doctoral fellows and students

regarding the translational process. SPARK participants receive modest funding, education

regarding translational research, and targeted mentorship on their specific projects. Over

fifty volunteers from the local biotechnology, pharmaceutical, and health care investment

community serve as advisors and mentors. SPARK is now in its ninth year. Approximately

60% of projects completing the program have been licensed and/or advanced to clinical

trials.

*************************************************************************

http://www.pbss.org/

10

QB3, Tuesday Mid Day, April 12, 2016

Topic: "Friends in Low Places: How I Leveraged Everyone I Know to Start a

Company"

Speaker: Colleen Cutcliffe, Whole Biome.

Date and Time: Tuesday, April 12, 2016 from 12:00 PM to 1:00 PM (PDT)

Location: Room 160, Helen Diller Bldg., 1450 3rd Street, San Francisco, CA 94158

Fee: $10 – general admission

Register at https://www.eventbrite.com/e/qed-colleen-cutcliffe-whole-biome-friends-

in-low-places-how-i-leveraged-everyone-i-know-to-start-a-tickets-

21392423314?mc_cid=e93dc63d3c&mc_eid=cb4c38a44a

Topic Description

To start a company, you have to solve challenges that range from the advanced, such

as technical innovation, to the mundane, such as opening a bank account. You must

overcome all the obstacles, but each requires a different skill set. On April 12,

Colleen Cutcliffe, co-founder and CEO of Whole Biome, will share stories of key

hurdles that she and her team ran into and the people who helped them succeed.

Everyone knows Step 1 is to have a great idea and Step 2 is to find funding. But

what about steps 1a. through 1z.? It’s always about who you know...but when you're

starting a company, the most helpful people are often not those you might have

predicted!

Speaker Bio

Colleen Cutcliffe is a Biochemist and Molecular Biologist with 10 years of experience

managing and directing fundamental biology research teams in the academic,

pharmaceutical and biotech sectors. Prior to co-founding Whole Biome, Colleen

served as the Senior Manager of Biology at Pacific Biosciences where she met and

collaborated with her fellow co-founders, John and Jim. Before her role at Pacific

Biosciences, Colleen served as a Scientist in the Parkinson's Disease discovery group

at Elan Pharmaceuticals. Colleen completed her postdoctoral research under

Elizabeth Perlman at Children's Memorial Hospital in Chicago, IL, her Ph.D in

Biochemistry and Molecular Biology under Cecile Pickart at Johns Hopkins University

and her B.A. in Biochemistry from Wellesley College.

************************************************************** Bio2Device Group, Tuesday Evening, April 12, 2016

JLABS Bay Area, Wednesday Mid Day, April 13, 2016

Topic: “Inspiring Leaders: Derek Herrera - Rebuilding Mind, Body and Business”

Speakers: Derek Herrera | CEO, Spinal Singularity [interviewer]; Renee Ryan | Vice

President, Venture Investments, Johnson & Johnson Innovation - JJDC

Date and Time: Wednesday, April 13, 2016 from 11:15 AM to 12:45 PM (PDT)

Agenda:

11:30 AM | Registration Opens, Lunch, and Networking

12:00 PM | Presentation, Interview and Q&A


Location: Plug and Play Tech Center, 440 N. Wolfe Rd, Sunnyvale, California

Fees:


11

$20 | Academic/Student Rate

$45 | At the door

Details and registration at http://www.eventbrite.com/e/inspiring-leaders-derek-

herrera-rebuilding-mind-body-and-business-tickets-21028235017?aff=weekly

Parking:

Plug and Play Tech Center onsite, additional parking in the Lowes parking lot.

Event Description

Being an entrepreneur takes resilience, perseverance, determination - all qualities

that a decorated, Marine Special Operations Team Leader would embody. Meet Derek

Herrera, Marine Captain turned entrepreneur - a man who epitomizes the idea of

turning a problem into an opportunity, and a truly inspiring leader. In June 2012,

after a six year career building and leading teams of Marines all over the world,

Captain Herrera was shot and paralyzed by enemy small arms fire while leading his

Marine Special Operations Team on patrol in Afghanistan. Derek returned to work

just 7 months after his injury, and 4 months after that completed his first para-

triathlon.

In true entrepreneur fashion Derek "pivoted," and after pursuing an MBA from UCLA

founded Spinal Singularity, who's first product, the Connected Catheter™, is the

world's first semi-permanent, fully internal, smart catheter system. Derek has led the

Spinal Singularity team to win numerous business plan competitions including being a

top 20 finalist in the MedTech Innovator program and winner of the primeUC

competition.

Join us for a fireside chat with Derek and experience the lessons he's learned about

selflessness, resilience and recovering from seemingly insurmountable odds.

The Inspiring Leader Series provides unrivaled access to been there done that

industry leaders in an intimate and unique setting. The highly sought after, featured

speakers share their forecasts and vision for the future as well as lessons learned

from the trenches. The series is designed to be an interactive and highly educational

experience for all who attend.

Speakers' Bios

Derek Herrera | CEO, Spinal Singularity

In November 2014, Captain Derek Herrera medically retired from Active Duty in the

US Marine Corps after 8.5 years of service as an Infantry and Special Operations

Officer. After graduating from the US Naval Academy in 2006, he has spent his first

six years in the Marine Corps building and leading teams of Marines, Sailors and

Soldiers all over the world. In June 2012, Derek was shot and paralyzed from the

chest down while leading his Marine Special Operations Team on patrol in the

Helmand River Valley, Afghanistan. He's received numerous personal decorations

including the Purple Heart, Combat Action Ribbon, Bronze Star (with combat

distinguishing device), Navy and Marine Corps Commendation Medal and the Navy

and Marine Corps Achievement Medal.

Captain Herrera graduated from the UCLA Anderson School of Management where he

earned an MBA, with a certificate in Entrepreneurship in 2015. While at UCLA, Derek

was awarded the John Wooden Global Leadership Fellowship for exceptional

leadership and was recognized by Poets and Quants as one of the top 50 EMBA

students of 2015.

Recently, he founded Spinal Singularity, a company that designs medical devices to

12

improve the quality of life for people with Spinal Cord Injury and Disease (SCI/D). In

May 2015, Derek led the Spinal Singularity team to win the UCLA Knapp Business

Plan Competition and the UCLA Student Engineering Venture Competition. Spinal

Singularity was a finalist in the MedTech Innovator program (top 20/292 companies)

and was awarded the Johnson & Johnson JLABS innovation award.

Derek has shared his story with the hopes of advocating for the Special Operations

and Paralysis communities and has spoken for many different groups and been

featured on National Media Outlets. He has also worked to support non-profit

organizations that he's passionate about including involvement on the Boards of The

MARSOC Foundation, American Technion Society and Renovating Hope.

[interviewer] Renee Ryan | Vice President, Venture Investments, Johnson & Johnson

Innovation - JJDC

Renee Compton Ryan joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in

2011. She is based in Silicon Valley, California and primarily supports the strategic

investment activities in medical devices and diagnostics.

Mrs. Ryan's background includes over 20 years of healthcare investment banking.

Most recently, she ran the medical device investment banking effort at R.W. Baird &

Co. Previously, she lead the West Coast medical device group at Jefferies & Co. and

was in the healthcare investment banking groups at Goldman Sachs and Credit

Suisse.

Mrs. Ryan received an MBA from Columbia Business School and a Bachelors degree

from Georgetown University.

*********************************************************************

Concord sfAWIS Networking Event , Wednesday Evening, April 13, 2016

Date and Time: Wednesday, April 13, 2016 - 6:00pm

Location: Valencia & Kebab Restaurant in San Francisco

Join SFAwis members for a fun evening of networking.

Event is free to attend but please register by April 6TH at eventbrite.com

search for "Concord Sfawis Networking Events."

Join sfAWIS members for a fun evening of networking! Event is free to attend but please

RSVP.

This is a great way to meet new people or strengthen existing relationships, hone your

“elevator pitch,” share advice, learn about career opportunities, hear new perspectives, and

learn more about AWIS.

*****************************************************

JLABS, Wednesday, April 20, 2016

Event: WORKSHOP 2 | IPO Readiness Bootcamp | April 20

Date and Time: Wednesday, April 20, 2016, 8:00 am

Agenda:

Event starts at Genentech Hall / Byers Auditorium

8:00 AM | Registration, Networking and Breakfast

9:00 AM | Welcome and Event introduction

Move to Mission Hall / Assigned rooms

9:40 AM | Get to your breakouts

9:50 AM | Breakout 1

10:50 AM | Get to your breakouts

11:00 AM | Breakout 2

12:00 PM | Lunch

12:50 PM | Breakout 3

1:50 PM | Coffee Break

13

2:00 PM | Get to your breakouts

2:10 PM Breakout 4


Facilitators:

Investment Banker:

Jennifer Jarrett | Managing Director , Citigroup's Health Care Investment Banking

Group

Attorneys:

Michael Tenta | Partner, Cooley LLP

Carlton Fleming | Associate, Cooley LLP

D&O Insurance:

Steve Sawyer | Partner & Executive Vice President, Woodruff-Sawyer &Co

Priya Cherian Huskins | Partner & Senior Vice President, Woodruff-Sawyer &Co

Auditors:


Jason Richter | National Federal Tax Services Transaction & Integration

Services, Deloitte Tax LLP

David Lyness | Director, Deloitte Tax Services

Locations:

UCSF Genentech Hall / Byers Auditorium: 600 16th St, San Francisco, CA

UCSF Mission Hall: 1599 4th St, San Francisco, CA

Day 2 Fees:

$65 | General Public (limited availability)

No Onsite Registration!

Register at http://www.eventbrite.com/e/how-to-ipo-series-tickets-

20106147027?aff=blast#Day1

Event Description

Are you on IPO watch? Whether IPO starts are up or down, and they will be up and

down, the most important time for your company to be IPO ready is now. Expertise

learned by being IPO ready benefits your firm regardless of your final go/ no-go IPO

decision. Join us for the ultimate IPO crash course to learn directly from the pros.

There are many stakeholders to manage when you prepare your company for an IPO

exit, including your investors, bankers, attorneys, auditors and insurance advisors.

We invited them all to share their insights, real stories, case studies and to answer

your pressing questions. Don't miss this opportunity to enhance your knowledge and

understanding of the step by step IPO process during our day-long program.

The Bootcamp features small group sessions with investment bankers, attorneys,

insurance and auditors/tax professionals to provide focus on individual needs.

Through direct interactions with these professionals, you will become confident in

building your IPO readiness plan as well as learn from group member experiences

and questions.

Key questions about preparing for the IPO process through IPO pricing and closing

will be answered including:

When and how to start IPO readiness process?

Are your investors and internal processes ready for the IPO?

Who from your company will be involved in the process and how much time

does it take?

14

How to manage your relationships with auditors during the process and what

to expect and when?

When and how to engage and choose your bankers?

What to expect from banker's due diligence?

IPO process detailed steps and timing

Registration statement drafting - who is involved, how long does it take, what

it includes and who will help with draft creation?

SEC review process of the registration statement

Roadshow - how to be best prepared for it?

IPO pricing and IPO closing - who is involved and what are their roles?

What do you need to know about D&O insurance? - Who sues you, and for

what, as a public company?

What are three pillars of protection to mitigate D&O risk?

What is the timeline for D&O Insurance for an IPO, including what are private

companies' transition issues?

Also, bring your own questions to receive direct, practical responses from our group

of professional advisors. The more you know, the better prepared your internal

resources and processes are to meet IPO challenges. After this program, you will be

equipped to build stronger and more efficient relationships with all stakeholders,

improve your IPO plan and more efficiently manage your IPO costs.

2016 Global sciences outlook: Moving forward with cautious optimism

Speakers' Biographies

Jennifer Jarrett | Managing Director , Citigroup's Health Care Investment Banking

Group

Jennifer is a Managing Director in Citigroup's Health Care Investment Banking Group.

At Citi, Jennifer focuses on raising capital for and advising companies in the

biotechnology sector. Prior to joining Citi in 2010, Jennifer was the Head of U.S.

Biotechnology at Credit Suisse where she spent 12 years. Jennifer started her career

working at Kidder Peabody and Merrill Lynch and has now spent almost 20 years in

investment banking, 16 of these years focused on the biotechnology sector. Since

Jennifer joined Citi in 2010, she has raised over $5B of capital for biotechnology

companies including several in the oncology sector. These companies include Ambit

Bio, Amgen, Epizyme, Five Prime, Halozyme, Jazz Pharmaceuticals, Medivation,

Mirati, Onconova, Puma Biotechnology and Tesaro. Jennifer has advised on a number

of M&A transactions over the course of her career. Jennifer is on the board of the

Clearity Foundation, a non-profit organization focused on improving treatment

options for ovarian cancer, and has organized several events to raise funds for

Clearity. Jennifer was elected to San Francisco Business Times Most Influential

Women in Business in 2014. Jennifer graduated from Dartmouth College, cum laude,

with a BA in Economics and received her MBA from the Stanford Graduate School of

Business. Jennifer is a native of Houston, Texas but has been in the Bay Area since

1996. In her free time, Jennifer enjoys golfing, skiing and running.

Michael Tenta | Partner, Cooley LLP

Michael E. Tenta is a partner in the Cooley Business department. He joined the Firm

in 2000 and is resident in the Palo Alto office. Mr. Tenta practices corporate and

securities law, representing public and private companies, investors and investment

banks in a variety of matters, including securities offerings, mergers and

acquisitions, and general corporate and commercial law. Prior to joining Cooley, Mr.

https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2016-life-sciences-outlook.pdf

15

Tenta was an associate at the law firm of Lawson Lundell in Vancouver, Canada,

where he advised both public and private companies in the technology,

manufacturing and resource sectors. Mr. Tenta graduated from the University of

Victoria Faculty of Law in 1997. During his legal studies, he spent a term working at

the Intellectual Property Policy Directorate of the Government of Canada and at the

University of the South Pacific Department of Law. Mr. Tenta graduated from Simon

Fraser University with a BS (Biology) in 1993. Mr. Tenta is a member of the State Bar

of California, the American Bar Association and the Law Society of British Columbia.

Mr. Tenta is not admitted to practice in Washington state.

Carlton Fleming | Associate, Cooley LLP

Carlton Fleming is an associate in Cooley's Business department and a member of the

Public Companies, Capital Markets and Emerging Companies practice groups. He

joined the Firm in 2012 and is resident in the Palo Alto office. Carlton practices

general corporate and securities law, representing both public and private companies

in a wide range of matters, including formation and financing activities, SEC

reporting and compliance, corporate governance and mergers and acquisitions. He

also represents investment banks and venture capital firms in public offerings and

private placements of equity and debt securities. Since 2012, Carlton has been

involved in over 25 IPOs and other public offerings, raising over $3 billion. Carlton

received a JD and an LLM in International and Comparative Law in 2007 from Duke

University School of Law. He received a BA in German and History in 2004 from Duke

University. Mr. Fleming is a member of the State Bar of California and the State Bar

of North Carolina.

Steve Sawyer | Partner & Executive Vice President, Woodruff-Sawyer &Co

A trusted advisor to Silicon Valley companies and beyond, Steve's creativity and

passion for solving clients' most complex risk challenges has led him to become an

industry innovator. Steve has been partnering with technology and life sciences

clients since joining the firm in 1981. He launched its Life Sciences Practice in 1991—

today one of the nation's largest. Under Steve's leadership, Woodruff-Sawyer as the

Biotechnology Industry Organization's (BIO's) as its West Coast risk management

partner. Steve works with organizations from new venture formation through IPO,

commercialization and international expansion. In addition to P&C, he has extensive

experience addressing D&O liability needs of public company clients. Steve also

founded Woodruff-Sawyer's CleanTech Practice in 2008. He worked with global

insurers to create innovative Performance Warranty programs for solar and other

clean tech projects, providing customized financial backstops to facilitate

"bankability" for securing financing for various projects. Steve is on Woodruff-

Sawyer's Board of Directors and has served on the board for BayBio, the

biotechnology trade organization for Northern California. He is active in various non-

profits and missions committed to pressing needs in our community and around the

world. Steve has a bachelor's degree from Stanford University and an MBA from

Northwestern University's Kellogg Graduate School of Management. He is a

designated Chartered Property and Casualty Underwriter (CPCU).

Priya Cherian Huskins, Esq. | Partner & Senior Vice President, Woodruff-Sawyer &Co

Priya Cherian Huskins is a recognized expert in D&O liability risk and its mitigation.

In addition to consulting on D&O insurance matters, she counsels clients on corporate

governance matters, including ways to reduce their exposure to shareholder lawsuits

and regulatory investigations. Priya is a frequent speaker on D&O issues and a

regular guest lecturer at Stanford's Directors' College, among others. She is also the

author of the D&O Notebook, a blog that monitors, curates and summarizes issues as

16

they arise in the areas of D&O liability, insurance and corporate governance. Priya

serves on the board of directors of Realty Income Corporation (NYSE: O) as well as

the Advisory Board for the Stanford University Rock Center for Corporate

Governance. Priya is also on the board of the of the Silicon Valley Directors'

Exchange (SVDX). Priya was listed as one of the "Most Influential Women in Bay Area

Business" by the San Francisco Business Times in 2012. She was a judge for the

prestigious Ernst & Young Entrepreneur of the Year award in Northern California from

2009-2011. Priya was named one of the "Top 100 Women of Influence in the Silicon

Valley" in 2009 by the San Jose/Silicon Valley Business Journal. Prior to joining

Woodruff-Sawyer, Priya practiced corporate and securities law at Wilson Sonsini

Goodrich & Rosati. Priya has worked with both public and private technology

companies through all stages of their development. Priya was awarded her juris

doctorate with honors from the Law School at the University of Chicago. She earned

her undergraduate degree with high honors from Harvard University. Priya is a

member of the California Bar.











Jason Richter | National Federal Tax Services Transaction & Integration Services,

Deloitte Tax LLP

Jason is a Senior Manager with National Federal Tax Services (Transaction &

Integration Services), Deloitte Tax LLP, and has over 14 years of professional

experience specializing in corporate tax matters including merger and acquisition

related due diligence, tax structuring, and tax modeling. Jason is primarily involved

in providing Section 382 and NOL consulting services including the day to day

management of the preparation of full Section 382 ownership change studies and the

computation of the related annual limitations. Jason is also responsible for the

preparation and review of quarterly Section 382 update analyses and the review of

studies in support of tax return preparation and financial statement reporting and

disclosure. Jason is frequently involved in providing Section 382 services as part of

due diligence for merger and acquisition transactions as well as NOL planning and

structuring. He serves a variety of public and private company clients. Jason has

been providing Section 382 services for over eleven years, authored several articles

in this area, and has appeared as a guest lecturer on the topic.

David Lyness | Director, Deloitte Tax Services

David leads Deloitte's Silicon Valley R&D tax credit practice. Over the past 20 years,

David has specialized in serving life science and other technology companies. Primary

focus areas include developing R&D tax credit claims and representing clients before

the IRS and state tax authorities. David is a member of the New York Bar, and has

degrees in accounting and law, including an LL.M (Tax) from New York University

School of Law.

**************************************************************

West Coast Chapter PDA, Thursday, April 21, 2016

17

Event: “Women in the Biopharmaceutical Industry:A Panel Discussion and Networking with

Company Leaders”

Date and Time: April 21 , 2016,6:00-9:30 PM

Agenda

6:00pm Registration and Networking

7:00pm Dinner

7:45pm Announcements

8:00pm Presentation and Discussion

9:30pm Closing

Location: Dominic's at Oyster Point | So. San Francisco, CA

Topic Description

Come hear the career stories, challenges and successes of our esteemed panelists as they

discuss their personal journeys into the biopharmaceutical industry. They'll discuss the

challenges women can expect to face upon entering the job market as well as share general

advice for women (and men) hoping to build their careers in the industry.

Registration

Pre-registration is $50 for PDA members and $60 for non-members (Credit/Cash/Check)

Additional $5 for Walk-in/At-Door registration.

There is a $15 discount for Government Employees and Students

PDA members: Please include your member ID number (after your name) in your

registration.

Use the following link to register.

If your device or email does not support registration/payment through the PayPal link, you

can submit registration requests via e-mail to [email protected] with "WCC PDA Dinner

RSVP" as the subject line. Indicated name and company affiliation for each registrant. If

you provide your information, a seat will be reserved for you.

Reserved seating is limited to the first 100 registrants! It is strongly encouraged that you

register in advance to ensure seating at this event, and to allow us to provide an accurate

head count for meals.

Speaker Bios

Melissa Morandi (Moderator) is currently the VP of Global Quality for Aegerion

Pharmaceuticals, and international company focused on the development and

commercialization of orphan drugs. Previously, she was VP of Quality at Acceleron Pharma,

and Vice President of Quality at Anesiva. Prior to joining Anesiva, Ms. Morandi held director

and managerial positions at Biogen, Genentech and Amgen. She holds a B.A. degree from

the University of California at Santa Barbara and a M.S. degree in Immunology from

California State University at Northridge.

Maura Lynch is the Director of business Development for Delta Project Management where

she oversees the business development and personnel management for the company. With

over 8 years of experience in the biotechnology and pharmaceutical industries, Ms. Lynch

has worked with many clients throughout the Bay Area including Genentech, Bayer,

Novartis, BioMarin and Boehringer-Ingelheim. She grew up in San Francisco, graduated

from the University of San Francisco and now calls Oakland home.

Sara Brien is currently Director of Technical Operations for Dynavax Technologies where she

is responsible for global project management and planning of CMC related product/process

development activities. Ms. Brien has 15 years of experience in pharmaceutical and

biotechnology manufacturing and supply chain operations. She has previously worked at


https://www.linkedin.com/title/director%2C-technical-operations?trk=mprofile_title

https://www.linkedin.com/company/590882?trk=prof-exp-company-name

18

Grifols and Novartis where she held positions of increasing responsibility. Prior to joining

Novartis Ms. Brien worked at Enzo Life Sciences, Assay Designs and Sanofi Pasteur.

Elizabeth Leininger is a consultant for Regulatory Affairs and Quality with more than 18

years of diverse experience. Previously she was VP Regulatory Affairs, Quality Assurance

and Clinical Operations at StemCells and VP of Regulatory Affairs and Quality at BAS

Medical. Formerly a consultant with The Biologics Consulting Group, Dr. Leininger has also

worked for the U.S. Food and Drug Administration, Chiron, and GlaxoSmithKline.

Elaine Eborall is currently Executive Director, Quality and Compliance for Ultragenyx

Pharmaceutical. Previously she has been with Genentech for 15 years where she was

responsible for the Global GMP Audit Program in the Americas and Asia Pacific regions.

Elaine holds a Bachelor’s of Science in Biology with a minor in Chemistry. She is certified as

a Quality Auditor by ASQ and holds an Advanced Certificate in Regulatory Affairs from the

University of San Diego. Prior to joining Genentech Elaine held positions at Astra-Zeneca

and Centaur Pharmaceuticals in Quality and Regulatory Affairs.

*********************************************************************

Bio-X Frontiers, Tuesday, April 26, 2016

Topic: “Integration Of Systems Biology, Tissue Engineering, And Microdevices For Drug

Development”

Pre-Seminar Speaker: Ovijit Chaudhuri, Department Of Mechanical Engineering

April 28, 2016

Seminar Speaker: Linda Griffith, Mit --Integration Of Systems Biology, Tissue Engineering,

And Microdevices For Drug Development

Date And Time: Tuesday, April 26, 2016, Noon

Location:

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

Small Lunch Served At 12:00��; Lectures Begin At12:15��

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

********************************************************

Naturejobs Career Expo, Wednesday, April 27,2016

Event: Career Expo

Date and Time: Wednesday, April 27, 2016l, 10 AM - 5 PM

Location: Contemporary Jewish Museum (736 Mission St, San Francisco, CA 94103)

Find details and registration at http://www.nature.com/naturejobs/career-

expo/event/naturejobs-career-expo-san-francisco/

Event Description: The Naturejobs Career Expo is the global career fair and conference for

the science community from Naturejobs and Natureconferences. The Naturejobs Career

Expo 2016, hosted for the first time in San Francisco, offers talented researchers an

excellent opportunity to meet a diverse selection of national and international employers

from academic institutions and scientific industries, such as pharmaceutical organizations,

digital technology companies, science publishing and more.

* Attend all conferences and workshops for free

* Meet employers face-to-face

* Benefit from one-to-one resume checking

* Network with leading scientific institutions

* Learn how to enhance your employability

19

* Maximize your career prospects

**************************************************************

BioScience Forum, Wednesday Evening, April 27, 2016

Topic “Discovery of GDC-0853: A Highly Potent, Selective and Non-Covalent Btk Inhibitor”

Speaker: Wendy Young, Ph.D., Vice President of Discovery Chemistry, Genentech

Date and Time: Wednesday, April 27, 2016, 6:00 PM - 9:00 PM 6 pm - 7 pm networking 7

pm - 8 pm dinner 8 pm - 9 pm presentation

Location: The Holiday Inn , 275 S Airport Blvd, South San Francisco, California 94080, USA

Fees: $50 before 9PM, Monday, April 25, $60 on-site $40 full-time students,pre-registration

$50 full-time students on-site, $3 service fee will be added to the pre-registration price

Register at BioSF.org

Topic Description

Bruton’s tyrosine kinase (Btk) plays a critical role in B cell maturation and survival in

addition to regulating myeloid cell inflammatory cytokine production, making it an attractive

target for the treatment of immunological disorders such as rheumatoid arthritis (RA) and

lupus, as well as B-cell malignancies. Mice deficient in BTK enzyme activity (X-linked

immune defect, xid) have marked depletion of B cell populations and are resistant to

developing collagen-induced arthritis and lupus. Male patients with BTK mutations have a

condition known as X-linked agammaglobulinemia, characterized by a severe block in B cell

development and diminished serum immunoglobulin levels; however, when treated with

intravenous immunoglobulins, they are generally able to lead fairly normal lives which

speaks to the potential safety of the target when modulating Btk activity as a therapeutic

intervention. To date, Imbruvica® is the only BTK inhibitor to launch in oncology

indications, while none have yet been approved in immunology indications. Thus there have

been significant efforts from the pharmaceutical community with the goal of identifying Btk

inhibitors for clinical development in immunology.

Dr. Young will describe the work at Genentech to develop a series of highly potent,

selective, non-covalent Btk inhibitors that have proven to be efficacious in several rodent

models of RA and lupus. Additionally, compounds in this chemical series were found to

remain highly active against the C481S Btk mutant that has been identified in patients that

have relapsed on Imbruvica®. In this presentation, the SAR, preclinical DMPK and

toxicology investigations leading up to the discovery and selection of the lead clinical

candidate, GDC-0853 will be described. Additionally, the initial results from Phase 1 clinical

trials will be shared.

Speaker Bio

Dr. Wendy B. Young, Ph.D. is currently Vice President of Discovery Chemistry at Genentech

in South San Francisco, where she directs a large group of medicinal, computational &

analytical chemists. Her department has been highly successful at discovering and moving

clinical candidates into clinical trials for many therapeutic indications including those in

oncology, immunology, and neuroscience.

Prior to Genentech, Dr. Young was Senior Director of Medicinal Chemistry and led discovery

efforts at Celera Genomics for twelve years where she focused on the discovery of protease

and kinase inhibitors for a variety of clinical indications.

Wendy received her Ph.D. from Princeton University in 1993 and completed a postdoctoral

fellowship at Memorial Sloan Kettering Cancer Center in 1995.

20

Wendy is listed as an inventor or author on over 70 patent and research publications and

has given presentations at many national and international meetings. Wendy was recently

elected as Vice Chair of the National ACS Medicinal Chemistry Division which will culminate

in her being Chair of the MEDI Division in 2017. Last year, Wendy was recognized by the

San Francisco Business Times as one of the San Francisco Bay Area’s “Most Influential

Business Women of 2015”. *************************************************************************************************************

Bio-X, Saturday, May 7, 2016

In vitro Vascularized Constructs as Models of Metastatic Cancer

Date and Time: Saturday, May 7, 2016, noon

Location:


SMALL LUNCH SERVED AT 12:00��; LECTURES BEGIN AT12:15��


Pre-Seminar Speaker: Alexander Dunn, Department of Chemical Engineering

May 19, 2016

Seminar Speaker: Roger Kamm, MIT

In vitro Vascularized Constructs as Models of Metastatic Cancer

*****************************

CABS, Saturday, May 7, 2017

Save the Date: 2016 BioPacific Conference

Date and Time: Saturday, May 7, 2016, 8 AM- 9 PM

Location: San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA 94402

Description:

Our meeting will showcase:

Winner of 2016 CABS K. Fong Award in Life Sciences

Most promising areas in life sciences

Opportunities and challenges for developing biopharmaceuticals in China

Cross border financing and entrepreneurship

Success stories of entrepreneurs and emerging companies

Confirmed Speakers and Panelists include:

Hari Kumar, CEO, Adheron Therapeutics

Piers Whitehead, EVP & CBO, PaxVax

Mark Selby, Ph.D., Senior Director of Immuno-Oncology, Bristol- Myers Squibb

Edward F. Chang, M.D., Associate Professor of Neurological Surgery and Physiology,

Co-Director, Center for Neural Engineering and Prostheses at UC Berkeley and UCSF,

New York Stem Cell Foundation- Robertson Investigator University of California,

San Francisco

Lei Stanley Qi, Ph.D., Assistant Professor, Department of Bioengineering and of

Chemical and Systems Biology, faculty fellow in the interdisciplinary Institute for

Chemistry, Engineering, and Medicine for Human Health

Shawn Qian, Ph.D., CEO, Neupharma

Xiaodong Yang, M.D., Ph.D., President and CEO, Apexigen

Xian-Ping Lu, Ph.D., Co-Founder, CEO and CSO, Chipscreen Biosciences

Dan Zhang, M.D., Ph.D., CEO, Fountain Medical Development

Yongmei "Alexis" Ji, Ph.D., MBA, Principal, WuXi Ventures

James Zhao, M.D., M.S., MBA, Founding Partner, LYFE Capital

Yuwen Liu, MBA, MS, Founding Partner, BoHe Angel Fund

Min Cui, Ph.D., Founding Partner and Managing Director, Decheng Capital

21

This highly anticipated full day event is expected to attract over 600 life science

professionals from San Francisco Bay Area as well as Pacific Rim countries.

Contact for Sponsorship/Exhibition Opportunities: [email protected]

*************************************************************************

*

sfAWIS, Wednesday Evening, May 11, 2016

Topic: "The Conflict Shift: from Conflict to Cooperation"

Speaker: Susan Berstein, MBA, PhD

Date and Time: Wednesday, May 11, 2016, 6:30 pm,:

*******************************************************************

HBA San Francisco, Thursday Morning, May 12, 2016

Event: “2016 Woman of Year Event – West”

Date and Time: Thursday, May 12, 2016, 8:00 – 11:00 am

8:00 - 8:30 AM Check in and networking

8:30 - 8:40 AM Welcome and opening remarks

8:40 - 9:25 AM Leadership panel

9:25 - 11:15 AM Live broadcast into WOTY, awards and networking

10:15- 11:00 AM Dress for success, raffle, networking and closing remarks

Event location

Genentech

611 Gateway Blvd., Building 82

South San Francisco, CA 94080

650-225-1000

Details and registration at

https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=C6A15543-C9DC-E511-A054-

0050569C00A7

Event Description

HBA celebrates Jennifer Cook, head of pharma for Europe region at Roche, as our 2016

Woman of the Year (WOTY). In addition, we will celebrate the 2016 Honorable Mentor

Jacopo Leonardi, executive vice president and president, Immunology at Baxalta

Incorporated, and nearly 100 Rising Stars and Luminaries.

At Genentech, we will participate in WOTY via a live satellite over breakfast. In addition to

the live feed, we will hear from a variety of senior leaders from Genentech, Deloitte and

other San Francisco companies and also provide the opportunity for networking throughout

the event.

******************************************************************

Stanford Medicine, Saturday, May 14, 2016

Topic: “Health Matters 2016”

Date and Time: Saturday, May 14, 9:00 a.m. – 2:00 p.m.

Location: Li Ka Shing Center for Learning and Knowledge, 291 Campus Drive, Stanford

Registration opens on April 1.

Rate

Member: $25

Non-member: $35

Student: $20

Genetech employee: $15

22

Details at http://healthmatters.stanford.edu/

Podcasts and videos of the 2015 event are also listed.

Topic Description

health matters is a free community event hosted by Stanford Medicine that explores the

latest advancements in medicine and the health topics that matter most to you and your

family.

****************************************************************

BioPharmaPM, Wednesday, May 18, 2016

Event: “2016 BioPharmaPM annual conference: "Strategic and Business Management,

Leadership, & Technical Project Management: Leveraging the PMI Talent Triangle in

BioPharma"”

Date: Wednesday, May 18, 2016.

We are also taking advantage of technology and holding the conference at two locations via

videoconference to enable and encourage greater participation. Our sponsors for the event,

Genentech and Pfizer, have graciously offered to host the event at their facilities in South

San Francisco and La Jolla, California, respectively. We will have speakers and networking at

each site, so if you are local to these facilities, or able to travel, please plan on attending.

Online registration for the event will launch with the website later in March - stay tuned for

more information!

*****************************************************************

JLABS, Thursday, May 19, 2016

Event: “WORKSHOP 3 | Lessons Learned: The IPO process from battle tested

Veterans”

Speakers:

Linda Bain | Chief Financial Officer, Codiak BioSciences read bio»

Isaac Ciechanover | President & CEO, Atara Biotherapeutics read bio»

[moderator] Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte &

Touche LLP

Date and Time: Thursday, May 19, 2016, 8:15 am

Agenda:

8:15 AM | Registration Opens, Breakfast and Networking

9:00 AM | Panel and Q&A

10:30 AM | Closing remarks and networking

11:00 AM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, CA

Day 3 Fees: $20 | General Public: $35 | At the door

Register at http://www.eventbrite.com/e/how-to-ipo-series-tickets-

20106147027?aff=blast#Day3

Event Description

There is nothing like experience! The final event in our 3 part IPO series with Deloitte

& Touche, LLP brings in two high profile C-level executives. They have gone through

the IPO experience and as IPO journey's go, their paths were different.

This breakfast event will take a look at two companies that recently went through

successful IPO's. The company leaders will share their insights from firsthand

experience on issues ranging from preparation to execution.

http://healthmatters.stanford.edu/

http://www.eventbrite.com/e/how-to-ipo-series-tickets-20106147027?aff=blast#s11

http://www.eventbrite.com/e/how-to-ipo-series-tickets-20106147027?aff=blast#s12

23

Topics include:

Hiring the right professional team

Managing the Board

The roadshow

Pricing, timing and market conditions

The surprises, pitfalls and lessons learned

With plenty of time for Q&A

Join us for an insider's look at the IPO!

Speakers' Biographies:

Linda Bain | Chief Financial Officer, Codiak BioSciences

Linda Bain joined Codiak from Avalanche Biotechnologies where, as chief financial

officer, she led a successful IPO and follow-on financing. She previously served as

vice president of finance, business operations and treasurer at Bluebird Bio. Ms. Bain

has held senior roles at Genzyme Corporation, including vice president of finance,

global manufacturing and operations and vice president of finance of Genzyme

Genetics. Earlier in her career, she served in senior finance roles at Fidelity

Investments and AstraZeneca Pharmaceuticals and as an auditor at Deloitte &

Touche.

Isaac Ciechanover, M.D. | President & CEO, Atara Biotherapeutics

Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion

to improve the practice of medicine. Motivated by the belief that the majority of

medical discoveries still lie ahead, he has dedicated the past 20 years to working

with entrepreneurs and life sciences organizations to advance medicine through

innovation and technology. He founded Atara Biotherapeutics in August 2012.

Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield &

Byers. Earlier as Celgene's Executive Director for Business Development, he

spearheaded the company's venture capital efforts and led licensing and M&A

activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was

Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has

also held business development and venture capital roles at Amylin Pharmaceuticals,

Pequot Ventures' healthcare practice and Pfizer. Intellectually curious (and

undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil.

in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical

College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling,

scuba diving and building Lego with his two children. His all-time favorite albums are

Pink Floyd's "The Dark Side of the Moon," Radiohead's "OK Computer" and Ruggero

Leoncavallo's Italian opera, Pagliacci, with Herbet Von Karajan conducting.











24

**********************************************************************

South Bay HBA, Saturday, June 4, 2016

Event: South Bay Coffee Chat

Location: Shoreline Lake American Bistro - 3160 N Shoreline Blvd., Mountain View, CA

To RSVP or for more information, please contact Meggin Taylor or Mary Dosunmu

*************************************************************************

BIO International Conference, June 6 – 9, 2016

Dates: June 6 – 9, 2016

Location: Moscone Convention Center, North, South and West Halls

Fees: Convention Access - $1,200, Members and 1,450, Non Members before April 16;

$1,400, Members and $1,750 for nonmembers after April 16 (see other package pricing at

http://convention.bio.org/register/)

*****************************************************************

BIO Career Fair, Thursday Afternoon, June 9, 2016

Event: BIO Career Fair

Date and Time: Thursday, June 9, 2016, 2:00 – 7:00 pm

Cost: Free

Details and registration at http://convention.bio.org/careerfair-jobseekers/

BIO is proud to announce the 2016 BIO Career Fair, Thursday June 9 from 2:00 - 7:00 pm.

As an extension of BIO’s online job board—Bio Jobs—the Career Fair will provide an

opportunity for meeting participants and top employers to discuss career opportunities..

The BIO Career Fair (is free) and will allow you access to many of the world’s leading life

science companies. A minimum of a 4-year life science degree OR a community college

biotech degree is recommended and military veterans are encouraged to apply. Details at

More information coming soon!

*********************************************************************

HPLC, Sunday, June 19, 2016

Topic: “HPLC 2016 - 44th International Symposium and Exhibit on High Performance Liquid

Phase Separations and Related Techniques”

Date and Time: Sunday, June 19, 2016 , 8:30 am

Location: Mariott San Francisco Marquis

The goal of HPLC 2016 is to bring together scientists who use and develop

HPLC, capillary electrophoresis, supercritical fluidic chromatography, microfluidics, and mass

spectrometry to exchange ideas, best practices, and

latest developments. The conference program is guided by emerging trends in

separations technology and their impact on science and society.

THREE SESSION TRACKS AT HPLC 2016:

Technology: Better, Faster, Quantitative Separations

Interface to MS: Improving Information Content

BioAnalysis and Applications: Impacting Science and Society

Topics include column and stationary phase technology, interface to mass spectrometry,

microfluidic systems, capillary electrophoresis, LCxLC, QA&QC methods, QbD in separations,

and application to real world problems. A special emphasis in applications will be on

bioanalysis including:

pharmaceuticals, antibody-drug conjugates, antibody characterization, biotechnology,

proteins and proteomics, glycomics, metabolomics and lipidomics, food and nutrition, well-

characterized biologicals, biofuels, environment, and toxicology.

Also Featuring:



http://convention.bio.org/register/

25

Tutorials, Short Courses, User Group Meetings, and Lunch Technical Sessions

For more information, visit: www.hplc2016.org

http://www.hplc2016.org/index.html

Type of Registration: Fees are posted under the "Online Registration" tab located at

www.HPLC2016.org.

Payment must be made by check or credit card payable in US Dollars and drawn on a US

bank (no bank wire transfers).

Registration is not accepted or acknowledged until payment is received.

By submitting this registration, you authorize the HPLC 2016 meeting to share your

information with attendees, etc.

Student Registrants: In order for the student rate to be accepted, must submit proof of

current full-time graduate or undergraduate, not postdoctoral, status at an academic

institution by providing both a copy of your Student I.D and a letter on university stationery

from your department chair along with the department chair contact details and email.

Email the letter and copy of the Student ID to [email protected].

All Oral and Poster Presenters: In order to present, the presenting author of each lecture

and poster must be registered as a conference attendee (not booth staff) and must

complete the registration process by paying online by April 18 to confirm intent to attend

and present at the meeting. If fees are not paid, submissions from that author will be

removed from the program.

Refund Policy: A processing fee of 20% will be collected on cancellations on or before April

1, 2016, after which the fees are non-refundable. Registration is transferable; must contact

Symposium Manager by no later than one week prior to the conference to transfer and

receive confirmation of the transfer of the registration ([email protected] or

telephone 301-668-6001).

HPLC 2016 Symposium/Exhibit Manager

Ms. Janet Cunningham

Barr Enterprises

www.LinkedIn.com/in/BarrEnterprises

phone 301-668-6001

[email protected]

www.HPLC2016.org

***********************************************************

PBSS Workshop, Monday, June 27, 2016

Workshop

Topic: “UHPLC in Biopharmaceutical Analysis: Benefits, Practices, Issues and

Implementation”

Speakers: Dr. Michael W. Dong, MWD Consulting

Date and Time: Monday, June 27, 2016, 8:45-12:30

Registration fee (US$): (USD$)Regular: $125; For vendor-show reps: $25; For unemployed

& students: $20; For major-sponsor rep (incl lunch): $0;


Major Sponsor: (1)Agilent

Vendor show vendors registered to date:



About the Topic

Ultra-high-pressure liquid chromatography (UHPLC) is the new standard HPLC platform

delivering higher performance with small-particle columns used on low-dispersion systems

with pressure limits of 15,000 – 23,000 psi. This intermediate-level 1/2-day training

workshop will provide a critical overview the fundamental concepts, benefits, potential

http://www.hplc2016.org/

http://www.hplc2016.org/index.html




http://www.linkedin.com/in/BarrEnterprises




26

issues, and best practices of UHPLC in pharmaceutical analysis of small molecule drugs and

recombinant biologics (monoclonal antibodies, mAbs)

Who Should Attend

This workshop is intended for analysts, managers, and researchers wishing to have a

thorough understanding the fundamentals and practices of UHPLC in pharmaceutical

analysis. A basic knowledge of HPLC is assumed and some practical hands-on experience is

highly recommended.

Workshop Agenda

UHPLC 1: Concept and Benefits

1. Overview and perspectives, Glossary, the modern HPLC platform with higher

performance, UHPLC concepts (the need for high pressure, void volume, peak

volume, instrumental bandwidth), UV flow cell design, dwell volume.

2. Benefits and case studies: Very fast separations with good resolution, very high

resolution analysis of complex samples, facilitating rapid method development,

flexibility to customize resolution, a modernized generic method for most drugs, a

greener HPLC platform.

UHPLC 2: Potential Issues, Practices, and implementation

1. Potential issues and how to mitigate (viscous heating, operating nuances,

compatibility to existing methods, injection precision, detector sensitivity vs. mixing

volumes.

2. Method translation (transfer) issues: method portability, method conversion

(translation), “What is method transfer?”, need for partial method validation, case

studies.

3. How to transition from HPLC to UHPLC, end-fittings, system performance tradeoffs,

Myths in UHPLC, references.

Learning Outcomes UHPLC in Biopharmaceutical Analysis

The attendee will learn the benefits, best practices and potential issues of UHPLC in

pharmaceutical analysis including method translation and how to get started in UHPLC.

About the Speakers

Dr. Michael W. Dong is a principal consultant in MWD Consulting focusing on consulting and

training services on HPLC/UHPLC, pharmaceutical analysis and drug quality. He was

formerly Senior Scientist in Analytical Chemistry and Quality Control at Genentech,

Research Director at Synomics Pharma, Research Fellow at Purdue Pharma, and Senior Staff

Scientist at Applied Biosystems / Perkin-Elmer. He holds a Ph.D. in Analytical Chemistry

from the City University of New York, and a certificate in Biotechnology from U. C. Santa

Cruz. He has 100+ publications including a bestselling book on chromatography (Modern

HPLC for Practicing Scientists). He is an editorial advisory board member of LCGC magazine

and American Pharmaceutical Review.

*************************************************************

PBSS, Friday MidDay, July 29, 2016

Seminar luncheon

Topic: “CRISPR gene editing platform development for drug discovery and validation”

Speakers: Benjamin Haley, PhD (Genentech)

Organizers:

Date: Friday, July 29, 2016, 11:00-13:30

Registration fee (US$): (USD$);


Major Sponsor:

Vendor show vendors registered to date:

27



******************************************************************

Bio2Device Group, Tuesday Evening, August 9, 2016

Topic: TBA

Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher

Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm

Date and Time: Tuesday, Oct. 13, 2015, 6:00pm

Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA

Cost:

$6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only

$20 - Late Registration and Non-Members

$25 - Walk-ins (as space permits)

Register at www.Bio2DeviceGroup.org

Speaker Bio

Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in

San Francisco and leads the company’s life sciences practice on the west coast of the

US. She joined the team in San Francisco in August 2012 after spending 5 years in

Simon-Kucher’s Boston office.

In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-

to-customer, market entry strategies, pricing and market access strategies, innovative

pricing strategies, product lifecycle strategies, licensing and valuation, market

forecasting and value communication, including global value story development and

implementation. She is a trusted advisor of leading pharmaceutical and biotech

companies across a wide range of therapeutic areas in all major healthcare markets

across the globe.

Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from

Yale University and a B.A. in Physics with honors from Wellesley College where she was

a Goldwater Scholar and a Schiff Fellow.

She is the author and coauthor of several scientific publications and has research

experience in theoretical and experimental physics, biophysics, cell biology, cancer

biology, genomics, proteomics, bioinformatics and biochemistry.


http://www.bio2devicegroup.org/